Following the completion of the spin-off of the Upjohn Business
(4) in the fourth quarter of 2020, Pfizer now operates as a focused innovative biopharmaceutical company engaged in the discovery, development, manufacturing, marketing, sales and distribution of biopharmaceutical products worldwide.
Revenues and expenses associated with the Upjohn Business
(4) for first-quarter 2020 have been recategorized as discontinued operations and excluded from Adjusted
(2) results. Pfizer’s Meridian subsidiary, the manufacturer of EpiPen and other auto-injector products, which had been reported within the results of the Upjohn Business
(4) in the first three quarters of 2020
, is now included within the Hospital therapeutic area for all periods presented.
Share this article
Share this article
PALO ALTO, Calif., May 3, 2021 /PRNewswire/ Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that Peginterferon Lambda (Lambda) will be added to the ongoing, multi-center, Phase 3
TOGETHER platform study in outpatients with COVID-19.
TOGETHER is an ongoing, multi-center, investigator-sponsored, randomized, placebo-controlled Phase 3 study evaluating multiple therapeutics in newly diagnosed, non-hospitalized patients with COVID-19, and will now include an investigational arm of Lambda as a single subcutaneous dose. The primary endpoint is a clinical outcome comparing emergency room visits and/or hospitalization in each active arm versus placebo. Each arm targets enrollment of up to 800 patients at high risk for developing complications from progression of COVID-19, w
Karyopharm Reports First Quarter 2021 Financial Results and Highlights Recent Company Progress Total Revenues of $23.3 Million for the First Quarter of 2021; XPOVIO® (selinexor) Net Product Sales of $21.7 Million Conditional Marketing Authorization Granted by the European Commission for NEXPOVIO® (selinexor) in Penta-Refractory Multiple Myeloma; European Decision for Expanded Multiple Myeloma Indication Expected in the Fourth Quarter of 2021 Richard Paulson Appointed Next President and Chief Executive Officer of Karyopharm Conference Call Scheduled for Today at 8:30 a.m. ET
News provided by
Share this article
Share this article
NEWTON, Mass., May 3, 2021 /PRNewswire/ Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported financial results for the quarter ended March 31, 2021. In addition, Karyopharm highlighted select corporate milestones, including details regarding the appo
Samsung Bioepis Announces Analytical Similarity Data on SB11 (ranibizumab) at the ARVO Annual Meeting 2021 morningstar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from morningstar.com Daily Mail and Mail on Sunday newspapers.